SPRY
ARS Pharmaceuticals, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $13 | $7.30 | -44% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $13 | $7.30 | -44% |
| Millennium Management re-entered | Q4 2024(8Q snapshot) | 6Q | $14 | $7.30 | -48% |
| AQR Capital Management re-entered | Q2 2025(8Q snapshot) | 4Q | $12 | $7.30 | -40% |
| Third Point | Q1 2026 | 1Q | $9.38 | $7.30 | -22% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments 2× in & out | Q4 2025 | Q1 2026 | → $9.38 | +14% |
| Duquesne Family Office | Q4 2024 | Q1 2025 | → $12 | -15% |
| Renaissance Technologies | Q3 2024 | Q1 2025 | → $12 | +10% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at ARS Pharmaceuticals, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jan 5, 2026 — the most recent Form 4 on file — not from today.
- Form 40001794284-26-000002Jan 5, 2026
- Form 40001951287-26-000002Jan 5, 2026
- Form 40001398595-26-000002Jan 5, 2026
- Form 40001380762-26-000002Jan 5, 2026
- Form 40001951238-26-000003Jan 5, 2026
- Form 40001951291-26-000002Jan 5, 2026
- Form 40001378550-26-000003Jan 5, 2026
- Form 40001380762-25-000005Nov 14, 2025
- Form 40001951238-25-000005Nov 14, 2025
- Form 40001580787-25-000004Nov 14, 2025
- Form 40001415889-25-022761Aug 22, 2025
- Form 40001415889-25-022760Aug 22, 2025
- Form 40001415889-25-022638Aug 21, 2025
- Form 40001415889-25-019321Jul 3, 2025
- Form 40001193805-25-000959Jul 1, 2025
Fundamentals
XBRL · ARS Pharmaceuticals, Inc.Annual figures sourced directly from ARS Pharmaceuticals, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for ARS Pharmaceuticals, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 15, 2026
- 8-KMaterial eventMay 15, 2026
- 8-KMaterial eventMay 13, 2026
- DEF 14AProxy statementApr 29, 2026
- 10-KAnnual reportMar 9, 2026
- 8-KMaterial eventMar 9, 2026
- 10-QQuarterly reportNov 10, 2025
- 8-KMaterial eventNov 10, 2025
- 8-KMaterial eventSep 29, 2025
- 8-KMaterial eventAug 28, 2025
- 10-QQuarterly reportAug 13, 2025
- 8-KMaterial eventAug 13, 2025
- 8-KMaterial eventJun 26, 2025
- 10-QQuarterly reportMay 14, 2025
- 8-KMaterial eventMay 14, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| AQR Capital Management | Q2 2026 | open | $7.43 | $7.30 | -2% |
| Third Point | Q1 2026 | open | $9.38 | $8.64 | -8% |
| Millennium Management | Q1 2026 | open | $9.38 | $7.30 | -22% |
| Two Sigma Investments | Q4 2025 | Q1 2026 | $8.21 | $9.38 | +14% |
| AQR Capital Management | Q2 2025 | Q4 2025 | $12 | $8.21 | -33% |
| Millennium Management | Q4 2024 | Q4 2025 | $14 | $8.21 | -42% |
| Duquesne Family Office | Q4 2024 | Q1 2025 | $14 | $12 | -15% |
| Citadel Advisors | Q3 2024 | open | $13 | $7.30 | -44% |
| Two Sigma Investments | Q3 2024 | Q3 2025 | $13 | $14 | +11% |
| D.E. Shaw | Q3 2024 | open | $13 | $7.30 | -44% |
| Renaissance Technologies | Q3 2024 | Q1 2025 | $11 | $12 | +10% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.